Консенсус керівних настанов з клінічної практики ISPAD 2018 р. Розділ 8. Цілі контролю глікемії та моніторинг глюкози для дітей, підлітків та молодих дорослих з діабетом
DOI:
https://doi.org/10.30978/UJPE2020-3-26Анотація
-Посилання
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329 (14):977-986.
Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. J Pediatr. 1994;125 (2):177-188.
Lachin J. M., Genuth S., Nathan D. M., Zinman B., Rutledge B. N. Effect of glycemic exposure on the risk of microvascular complications In the diabetes control and complications trial-revisited. Diabetes. 2008;57 (4):995-1001.
Nathan D. M., Zinman B., Cleary P. A. et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169 (14):1307-1316.
White N. H., Cleary P. A., Dahms W., Goldstein D., Malone J., Tamborlane W. V. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139 (6):804-812.
Hofer S. E., Raile K., Fröhlich-Reiferer E et al. Tracking of metabolic control from childhood to young adulthood in type 1 diabetes. J Pediatr. 2014;165 (5):956-966.
Samuelsson U., Steineck I., Gubbjornsdottir S. A high mean-HbA1c value 3-15 months after diagnosis of type 1 diabetes in childhood Is related to metabolic control, macroalbuminuria, and retinopathy in early adulthood-a pilot study using two nation-wide population based quality registries. Pediatr Diabetes. 2014;15 (3):229-235.
Donaghue К. С., Fung A. T., Hing S et aI. The effect of prepubertal diabetes duration on diabetes. Microvascular complications In early and late adolescence. Diabetes Care. 1997;20 (l):77-80.
Genuth S. M., Backlund J. Y., Bayless M et al. Effects of prior Intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes In the DCCT/EDIC. Diabetes. 2013;62 (10):3561-3569.
Writing Team for the DCCT/EDIC Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA. 2003;290 (16):2159-2167.
Writing Team for the DCCT/EDIC Research Group, Gubitosi-Klug R. A., Sun W et al. Effects of prior intensive insulin therapy and risk factors on patient-reported visual function outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. JAMA Ophthalmol. 2016;134 (2):137-145.
Writing Group for the DCCT/EDIC Research Group, Orchard T. J., Nathan D. M. et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313 (1):45-53.
Arbelaez A. M., Semenkovich K., Hershey T. Glycemic extremes in youth with T1DM: the structural and functional integrity of the developing brain. Pediatr Diabetes. 2013;14 (8):541-553.
Barnea-Goraly N., Raman M., Mazaika P et al. Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care. 2014;37 (2):332-340.
Broadley M. M., White M. J., Andrew B. A systematic review and meta-analysis of executive function performance in type 1 diabetes mellitus. Psychosom Med. 2017. 79 (6):684-696.
Perantie D. C., Wu J., Koller J. M. et al. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care. 2007;30 (9):2331-2337.
Ryan C. M., van Duinkerken E., Rosano C. Neurocognitive consequences of diabetes. Am Psychol. 2016;71 (7):563-576.
Foland-Ross L. C., Reiss A. L., Mazaika P. K. et al. Longitudinal assessment of hippocampus structure in children with type 1 diabetes. Pediatr Diabetes. 2018. https://doi.org/10.1111/pedi.12683.
Aye T., Barnea-Goraly N., Ambler C et al. White matter structural differences in young children with type 1 diabetes: a diffusion tensor imaging study. Diabetes Care. 2012;35 (11):2167-2173.
Ryan C. M. Why is cognitive dysfunction associated with the development of diabetes early in life? The diathesis hypothesis. Pediatr Diabetes. 2006;7 (5):289-297.
Cooper M. N., O’Connell S. M., Davis E. A., Jones T. W. A population-based study of risk factors for severe hypoglycaemia in a contemporary cohort of childhood-onset type 1 diabetes. Diabetologia. 2013;56:2164-2170.
Downie E., Craig M. E., Hing S., Cusumano J., Chan A. K., Donaghue K. C. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care. 2011;34 (11):2368-2373.
Johnson S. R., Cooper M. N., Jones T. W., Davis E. A. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia. 2013;56:2392-2400.
Ly T. T., Nicholas J. A., Retterath A., Lim E. M., Davis E. A., Jones T. W. Effect of sensor-augmented pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240-1247.
Bohn B., Karges B., Vogel C et al. 20 years of pediatric benchmarking in Germany and Austria: age-dependent analysis of longitudinal follow-up in 63,967 children and adolescents with type 1 diabetes //PLoS One. 2016;11 (8):e0160971.
Haynes A., Hermann J. M., Miller K. M. et al. Severe hypoglycemia rates are not associated with HbA1c: a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes. 2017;18 (7):643-650.
Karges B., Kapellen T., Wagner V. M. et al. for the DPV Initiative Glycated hemoglobin A1c as a risk factor for severe hypoglycemia in pediatric type 1 diabetes. Pediatr Diabetes. 2017;18 (1):51-58.
Karges B., Rosenbauer J., Kapellen T et al. Hemoglobin A1c levels and risk of severe hypoglycemia in children and young adults with type 1 diabetes from Germany and Austria: a trend analysis in a cohort of 37,539 patients between 1995 and 2012. PLoS Med. 2014;11 (10):e1001742.
Davis E. A., Soong S. A., Byrne G. C., Jones T. W. Acute hyperglycaemia impairs cognitive function in children with IDDM. J Pediatr Endocrinol Metab. 1996;9 (4):455-461.
Martin D. D., Davis E. A., Jones T. W. Acute effects of hyperglycemia in children with type 1 diabetes mellitus: the patient’s perspective. J Pediatr Endocrinol Metab. 2006;19:927-936.
Nathan D. M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R. J. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31 (8):1473-1478.
Bergenstal R. M., Gal R. L., Connor C. G. et al. for the T1D Exchange Racial Differences Study Group. Racial differences in the relationship of glucose concentrations and hemoglobin A1c levels. Ann Intern Med. 2017;167 (2):95-102.
Beck R. W., Connor C. G., Mullen D. M., Wesley D. M., Bergenstal R. M. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care. 2017;40 (8):994-999.
Herman W. H. Do race and ethnicity impact hemoglobin A1c independent of glycemia?. J Diabetes Sci Technol. 2009;3 (4):656-660.
Venkataraman K., Kao S. L., Thai A. C. et al. Ethnicity modifies the relation between fasting plasma glucose and HbA1c in Indians, Malays and Chinese. Diabet Med. 2012;29 (7):911-917.
Wilson D. M., Xing D., Beck R. W. et al. Hemoglobin A1c and mean glucose in patients with type 1 diabetes: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care. 2011;34 (3):540-544.
Wilson D. M., Xing D., Cheng J et al. for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring randomized trial. Diabetes Care. 2011;34 (6):1315-1317.
Hempe J. M., Gomez R., McCarter R. J. Jr, Chalew S. A. High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat. 2002;16 (5):313-320.
Haller M. J., Stalvey M. S., Silverstein J. H. Predictors of control of diabetes: monitoring may be the key. J Pediatr. 2004;144:660-661.
Miller K. M., Beck R. W., Bergenstal R. M. et al. for the T1D Exchange Clinic Network. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D Exchange clinic registry participants. Diabetes Care. 2013;36 (7):2009-2014.
Redondo M. J., Connor C. G., Ruedy K. J. et al. for the Pediatric Diabetes Consortium. Pediatric diabetes consortium type 1 diabetes new onset (NeOn) study: factors associated with HbA1c levels one year after diagnosis. Pediatr Diabetes. 2014;15 (4):294-302.
Ziegler R., Heidtmann B., Hilgard D et al. for the DPV-Wiss-Initiative Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2011;12 (1):11-17.
Tsalikian E., Kollman C., Tamborlane W. B. et al. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care. 2006;29 (10):2200-2204.
Bergenstal R., Pearson J., Cembrowski G. S., Bina D., Davidson J., List S. Identifying variables associated with inaccurate self-monitoring of blood glucose: proposed guidelines to improve accuracy. Diabetes Educ. 2000;26:981-989.
Schmid C., Haug C., Heinemann L., Freckmann G. System accuracy of blood glucose monitoring systems: impact of use by patients and ambient conditions. Diabetes Technol Ther. 2013;15 (10):889-896.
FDA. Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use. 2014. Guidance for Industry and Food and Drug Administration Staff. https://www.fda.gov/downloads/ucm380327.pdf. Accessed August 18, 2018.
Roberts A. J., Taplin C. E. Exercise in youth with type 1 diabetes. Curr Pediatr Rev. 2015;11 (2):120-125.
Chiang J. L., Kirkman M. S., Laffel L. M., Peters A. L., Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37 (7):2034-2054.
Beckles Z. L., Edge J. A., Mugglestone M. A., Murphy M. S., Wales J. K. Guidelines Development Group. Diagnosis and management of diabetes in children and young people: summary of updated NICE guidance. BMJ. 2016;352:i139.
American Diabetes Association. 12. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41- (suppl 1):S126-S136.
Skinner T. C., Lange K. S., Hoey H et al. The Hvidoere Study Group Targets and teamwork: understanding differences in pediatric diabetes centers treatment outcomes. Pediatr Diabetes. 2018;19 (3):559-565.
Cameron F. J., de Beaufort C., Aanstoot H. J. et al. The Hvidoere International Study Group. Lessons from the Hvidoere International Study Group on childhood diabetes: be dogmatic about outcome and flexible in approach. Pediatr Diabetes. 2013;14 (7):473-480.
Phelan H., King B., Anderson D., Crock P., Lopez P., Smart C. Young children with type 1 diabetes can achieve glycemic targets without hypoglycemia: results of a novel intensive diabetes management program. Pediatr Diabetes. 2018;19 (4):769-775.
Haviland N., Walsh J., Roberts R., Bailey T. S. Update on clinical utility of continuous glucose monitoring in type 1 diabetes. Curr Diab Rep. 2016;16 (11):115.
Sparacino G., Zanderigo F., Corazza S., Maran A., Facchinetti A., Cobelli C. Glucose concentration can be predicted ahead in time from continuous glucose monitoring sensor time-series. IEEE Trans Biomed Eng. 2007;54:931-937.
Bailey T. S., Chang A., Christiansen M. Clinical accuracy of a continuous glucose monitoring system with an advanced algorithm. J Diabetes Sci Technol. 2015;9 (2):209-214.
Bergenstal R. M., Klonoff D. C., Garg S. K. et al. ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369 (3):224-232.
Maahs D. M., Calhoun P., Buckingham B. A. et al. In Home Closed Loop Study Group. A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes. Diabetes Care. 2014;37:1885-1891.
Chase H. P., Kim L. M., Owen S. L. et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics. 2001;107 (2):222-226.
Mastrototaro J. J., Cooper K. W., Soundararajan G., Sanders J. B., Shah R. V. Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study. Adv Ther. 2006;23 (5):725-732.
Deiss D., Bolinder J., Riveline J. P. et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care. 2006;29 (12):2730-2732.
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane W. V., Beck R. W. et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359 (14):1464-1476.
Ahn D., Pettus J., Edelman S. Unblinded C. G.M should replace blinded CGM in the clinical management of diabetes. J Diabetes Sci Technol. 2016;10 (3):793-798.
Garg S., Zisser H., Schwartz S et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29 (1):44-50.
Gutierrez A. Dexcom G5 Mobile Continuous Glucose Monitoring System In. Letter ed. https://www.accessdata.fda.gov/cdrh_docs/ pdf12/P120005S041a.pdf 2016:1-4. Accessed August 19, 2018.
Petrie J. R., Peters A. L., Bergenstal R. M., Holl R. W., Fleming G. A., Heinemann L. Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia. 2017;60 (12):2319-2328.
Steck A. K., Dong F., Taki I., Hoffman M., Klingensmith G. J., Rewers M. J. Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes. Diabetes Care. 2014;37:2031-2033.
Borowiec M., Mysliwiec M., Fendler W et al. Phenotype variability and neonatal diabetes in a large family with heterozygous mutation of the glucokinase gene. Acta Diabetol. 2011;48 (3):203-208.
Jefferies C., Solomon M., Perlman K., Sweezey N., Daneman D. Continuous glucose monitoring in children and adolescents with cystic fibrosis. J Pediatr. 2005;147:396-398.
O’Riordan S. M., Hindmarsh P., Hill N. R. et al. Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study. Diabetes Care. 2009;32 (6):1020-1022.
Iscoe K. E., Campbell J. E., Jamnik V., Perkins B. A., Riddell M. C. Efficacy of continuous real-time blood glucose monitoring during and after prolonged high-intensity cycling exercise: spinning with a continuous glucose monitoring system. Diabetes Technol Ther. 2006;8:627-635.
Mozdzan M., Ruxer J., Loba J., Siejka A., Markuszewski L. Safety of various methods of intense insulin therapy in hospital condition assessed by hypoglycemic episodes detected with the use of continuous glucose monitoring system. Adv Med Sci. 2006;51:133-136.
Bergenstal R. M., Tamborlane W. V., Ahmann A et al. STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363 (4):311-320.
Perkins B. A., Halpern E. M., Orszag A et al. Sensor-augmented pump and multiple daily injection therapy in the United States and Canada: post-hoc analysis of a randomized controlled trial. Can J. Diabetes. 2015;39 (1):50-54.
Beck R. W., Buckingham B., Miller K et al. Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2009;32 (11):1947-1953.
Weinzimer S., Xing D., Tansey M et al. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes. 2009;10 (2):91-96.
Cemeroglu A. P., Stone R., Kleis L., Racine M. S., Pstellon D. C., Wood M. A. Use of a real-time continuous glucose monitoring system in children and young adults on insulin pump therapy: patients’ and caregivers’ perception of benefit. Pediatr Diabetes. 2010;11:182-187.
Tanenbaum M. L., Hanes S. J., Miller K. M., Naranjo D., Bensen R., Hood K. K. Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabetes Care. 2017;40 (2):181-187.
Miller K. M., Foster N. C., Beck R. W. et al. T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U. S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38 (6):971-978.
Tylee T. S., Trence D. L. Glycemic variability: looking beyond the A1C. Diabetes Spectr. 2012;25 (3):149-153.
Danne T., Nimri R., Battelino T et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40 (12):1631-1640.
Lachin J. M., Bebu I., Bergenstal R. M. et al. DCCT/EDIC Research Group. Association of glycemic variability in type 1 diabetes with progression of microvascular outcomes in the diabetes control and complications trial. Diabetes Care. 2017;40 (6):777-783.
Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011;7:385-395.
Edge J., Acerini C., Campbell F et al. An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child. 2017;102 (6):543-549.
Bailey T., Bode B. W., Christiansen M. P., Klaff L. J., Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17 (11):787-794.
Bolinder J., Antuna R., Geelhoed-Duijvestijn P., Kroger J., Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388 (10057):2254-2263. Accessed August 19, 2018.
Heinemann L., Freckmann G. CGM versus FGM; or, continuous glucose monitoring is not flash glucose monitoring. J Diabetes Sci Technol. 2015;9 (5):947-950.
Hirsch I. B., Verderese C. A. Professional flash continuous glucose monitoring with ambulatory glucose profile reporting to supplement A1c: rationale and practical implementation. Endocr Pract. 2017;23 (11):1333-1344.
FDA. FDA approves first continuous glucose monitoring system for adults not requiring blood sample calibration. FDA News Release 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnoun cements/ucm577890.htm. Accessed August 19, 2018.
National Institute for Health and Care Excellence. FreeStyle Libre for glucose monitoring. 2017. https://www.nice.org.uk/guidance/ mib110/resources/freestyle-libre-for-glucosemonitoring- pdf-2285963268047557. Accessed July 9, 2018.
Tahara Y., Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18 (4):440-447.
Hoelzel W., Weykamp C., Jeppsson J. O. et al. IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem. 2004. 50 (1):166-174.
Kobold U., Jeppsson J. O., Dulffer T., Finke A., Hoelzel W., Meidema K. Candidate reference methods for hemoglobin A1c based on peptide mapping. Clin Chem. 1997. 43:1944-1951.
Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care. 2007;30 (9):2399-2400.
Driskell O. J., Holland D., Waldron J. L. et al. Reduced testing frequency for glycated hemoglobin, HbA1c, is associated with deteriorating diabetes control. Diabetes Care. 2014;37 (10):2731-2737.
Schwandt A., Best F., Biester T et al. Both the frequency of HbA1c testing and the frequency of self-monitoring of blood glucose predict metabolic control: A multicentre analysis of 15 199 adult type 1 diabetes patients from Germany and Austria. Diabetes Metab Res Rev. 2017. 33 (7):e2908.
Nathan D. M., McGee P., Steffes M. W., Lachin J. M., for the DCCT/EDIC Research Group. Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study. Diabetes. 2014;63 (1):282-290.
Selvin E., Rawlings A. M., Grams M et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014. 2 (4):279-288.
Gubitosi-Klug R. A. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37:44-49.
Carlsen S., Skrivarhaug T., Thue G et al. Glycemic control and complications in patients with type 1 diabetes — a registry-based longitudinal study of adolescents and young adults. Pediatr Diabetes. 2017;18 (3):188-195.
Charalampopoulos D., Hermann J. M., Svensson J et al. Exploring variation in glycemic control across and within eight high-income countries: a cross-sectional analysis of 64,666 children and adolescents with type 1 diabetes. Diabetes Care. 2018;41 (6):1180-1187.
Clements S. A., Anger M. D., Bishop F. K. et al. Lower A1c among adolescents with lower perceived A1c goal: a cross-sectional survey. Int. J Pediatr. Endocrinol. 2013. 2013 (1):17.
Swift P. G., Skinner T. C., de Beaufort C. E. et al. Hvidoere Study Group on Childhood Diabetes. Target setting in intensive insulin management is associated with metabolic control: the Hvidoere childhood diabetes study group Centre differences study 2005. Pediatr Diabetes. 2010;11 (4):271-278.
Hanberger L., Samuelsson U., Bertero C., Ludvigsson J. The influence of structure, process, and policy on HbA (1c) levels in treatment of children and adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2012. 96 (3):331-338.
National Paediatric Diabetes Audit Royal College of Paediatrics and Child Health. National Paediatric Diabetes Audit 2015-16 Report 1: Care Processes and Outcomes. 2017. Monograph. https://www. rcpch.ac.uk/sites/default/files/NPDA_2015-16_audit_report.pdf. Accessed August 19, 2018.
Mohsin F., Craig M. E., Cusumano J et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care. 2005;28 (8):1974-1980.
DiLiberti J. H., Lorenz R. A. Long-term trends in childhood diabetes mortality: 1968-1998. Diabetes Care. 2001;24:1348-1352.
Swedish National Guidelines on Pediatric Diabetes 2017. http://endodiab.barnlakarforeningen.se/wp-content/uploads/sites/9/2015/03/ VP_2016_Kap8-Uppf-Glucoskontroll.pdf. Accessed August 19, 2018.
Forga L., Goni M. J., Ibanez B., Cambra K., Garcia-Mouriz M., Iriarte A. Influence of age at diagnosis and time-dependent risk factors on the development of diabetic retinopathy in patients with type 1 diabetes. J Diabetes Res. 2016;2016:9898309.
Porta M., Schellino F., Montanaro M et al. Prevalence of retinopathy in patients with type 1 diabetes diagnosed before and after puberty. Acta Diabetol. 2014;51 (6):1049-1054.
Chase H. P., Lockspeiser T., Peery B et al. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care. 2001;24 (3):430-434.
Davis E. A., Keating B., Byrne G. C., Russell M., Jones T. W. Impact of improved glycaemic control on rates of hypoglycaemia in insulin dependent diabetes mellitus. Arch Dis Child. 1998;78 (2):111-115.
Cengiz E., Xing D., Wong J. C. et al. for the T1D Exchange Clinic Network. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D exchange clinic registry. Pediatr Diabetes. 2013;14 (6):447-454.
De Beaufort C. E., Swift P. G., Skinner C. T. et al. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere study group on childhood diabetes. Diabetes Care. 2007;30 (9):2245-2250.
Fanelli C. G., Epifano L., Rambotti A. M. et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42 (11):1683-1689.
Phillip M., Battelino T., Atlas E et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368 (9):824-833.
Cranston I., Lomas J., Maran A., Macdonald I., Amiel S. A. Restoration of hypoglycaemia awareness in patients with long-duration insulindependent diabetes. Lancet. 1994;344 (8918):283-287.
Simonson D. C., Tamborlane W. V., DeFronzo R. A., Sherwin R. S. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type 1 diabetes. Ann Intern Med. 1985;103:184-190.
Corathers S. D., Schoettker P. J., Clements M. A. et al. Health-system-based interventions to improve care in pediatric and adolescent type 1 diabetes. Curr Diab Rep. 2015;15 (11):91.
Hanberger L., Samuelsson U., Holl R. W. et al. Type 1 diabetes during adolescence: international comparison between Germany, Austria, and Sweden. Pediatr Diabetes. 2017.
Maahs D. M., Hermann J. M., DuBose S. N. et al. Contrasting the clinical care and outcomes of 2,622 children with type 1 diabetes less than 6 years of age in the United States T1D exchange and German/Austrian DPV registries. Diabetologia. 2014;57 (8):1578-1585.
